Antagonizing CD105 and androgen receptor to target stromal-epithelial interactions for clinical benefit

• Published in: Molecular therapy Vol. 31; no. 1; pp. 78 - 89
• Main Authors: Smith, Bethany N., Mishra, Rajeev, Billet, Sandrine, Placencio-Hickok, Veronica R., Kim, Minhyung, Zhang, Le, Duong, Frank, Madhav, Anisha, Scher, Kevin, Moldawer, Nancy, Oppenheim, Amy, Angara, Bryan, You, Sungyong, Tighiouart, Mourad, Posadas, Edwin M., Bhowmick, Neil A.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 04.01.2023; American Society of Gene & Cell Therapy
• Subjects: Androgen Receptor Antagonists - therapeutic use; androgen receptor splice variants; Antibodies, Neutralizing - therapeutic use; cancer-associated fibroblasts; CD105; Drug Resistance, Neoplasm; endoglin; Endoglin - antagonists & inhibitors; Humans; Male; Neoplastic Cells, Circulating - metabolism; Original; PCa; Prostatic Neoplasms, Castration-Resistant - drug therapy; Prostatic Neoplasms, Castration-Resistant - metabolism; Protein Isoforms; Receptors, Androgen - genetics; Receptors, Androgen - metabolism; RNA-Binding Proteins; androgen receptor splice variants; cancer-associated fibroblasts; CD105; endoglin; PCa

Androgen receptor signaling inhibitors (ARSIs) are standard of care for advanced prostate cancer (PCa) patients. Eventual resistance to ARSIs can include the expression of androgen receptor (AR) splice variant, AR-V7, expression as a recognized means of ligand-independent androgen signaling. We demo...